|                  | Denosumab (N = 11) | Zoledronate (N = 12) | Total (N = 23) | P-value \(^a\) |
|------------------|--------------------|----------------------|----------------|----------------|
| **Baseline**     | 0.10 (0.10-0.30)   | 0.20 (0.10-0.20)     | 0.20 (0.10-0.20) | 0.750          |
| **Week 4**       | 0.2 (0.10-0.40)    | 0.20 (0.10-0.20)     | 0.2 (0.10-0.25)  | 0.483          |
| Change from baseline | 0 (0-0.15)         | 0 (-0.10-0.07)       | 0 (-0.05-0.10)   | 0.641          |
| %Change from baseline | 0 (-112.50)       | 0 (-50.0-75.0)       | 0 (-25.0-62.5)   | 0.589          |
| P-value (baseline - week 4) \(^b\) | 0.130              | 0.782                | 0.524           |                |
| **Week 24**      | 0.20 (0.05-0.30)   | 0.30 (0.13-0.60)     | 0.20 (0.10-0.50) | 0.826          |
| Change from baseline | 0.10 (-0.20-0.15) | 0.15 (0-0.47)        | 0.10 (0-0.30)    | 0.535          |
| %Change from baseline | 100 (-50-100)      | 100 (0-275)          | 100.0 (0-150.0)  | 0.154          |
| P-value (baseline - week 24) \(^b\) | 0.966              | 0.175                | 0.289           |                |
| **Week 48**      | 0.10 (0.10-0.15)   | 0.20 (0.20-0.30)     | 0.20 (0.10-0.25) | 0.062          |
| Change from baseline | 0 (-0.20-0.05)    | 0 (0-0.10)           | 0 (-0.05-0.10)   | 0.089          |
| %Change from baseline | 0 (-62.5-50)      | 0 (0-87.5)           | 0 (-25.0-75.0)   | 0.138          |
| P-value (week 0 - week 48) \(^b\) | 0.802              | 0.243                | 0.622           |                |

\(^a\)P-values were derived from Student’s t-test in analyzing between groups.

\(^b\)P-values were derived from Wilcoxon signed-rank test in analyzing within groups.